When reading that chart, keep in mind that lymphadenopathy is just swelling of the lymph nodes, and is an expected and not-serious effect of the vaccine; it's a sign that an immune response is being triggered.
Citing your source:
2.7 events per 100,000 persons (vaccinated)
11.0 events per 100,000 persons (SarS-COV2 positive)
This already doesn't look that great, considering that the risk of a PCR-confirmed infection is not 100%. More importantly, it doesn't take into account age.
The age group at highest risk from Myocarditis following vaccination is 16-17 year-old males, latest numbers from the CDC[1]:
5.1/71.5 events* per 100,000 first/second Pfizer doses administered (within 7 days)
This has a strong bias towards the second dose, it's not clear yet how booster shots fare here, which may need to be administered at 5 months intervals.
It stands to reason that the Myocarditis risk from COVID infection in that age group should also be higher, but it's not clear whether the benefit outweighs the risk in that age/sex group, considering that both infection count and side-effect cases tend to be under-reported.
*) It's not clear whether that number includes the cases "under investigation". If so, this would further raise the risk by up to 66%.
[1]: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-... (Page 13)